Investors
News Releases
- November 12, 2020Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer’s and Parkinson’s Diseases
- November 2, 2020Annovis Bio CEO to Present at Meridian Clinical Trials Summit
- October 29, 2020Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer’s Disease after COVID-Related Delay
- October 22, 2020Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award
- October 20, 2020Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times’ Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair
- October 15, 2020Annovis Bio Provides Third Quarter 2020 and Year-to-Date Business Highlights
- October 12, 2020Annovis Bio to Present at the 2020 BIO Investor Forum
- September 29, 2020Annovis Bio Demonstrates Improved Axonal Transport in Nerve Cells and Brain of Down Syndrome Mice, an Animal Model of Alzheimer’s Disease
- September 3, 2020Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
- September 1, 2020Annovis Bio Begins Treatment of First Patients in its Phase 2a Alzheimer’s and Parkinson’s Trial
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top